Plain-English translation of NCT05289063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Sleep apnea damages the blood vessels in your body, which increases your risk of heart disease even when treated with a CPAP machine. This study is testing whether atorvastatin, a medication that lowers cholesterol and reduces inflammation in blood vessels, can help protect your heart when added to CPAP treatment.
Current CPAP therapy doesn't fully protect people with sleep apnea from heart disease, and researchers believe this medication may fix the underlying blood vessel damage that CPAP alone cannot address.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the study medication or a placebo pill once daily while continuing your CPAP therapy. The study follows you over time to see whether the medication improves how your blood vessels function and reduces your heart disease risk compared to CPAP alone.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Columbia University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~110 participants
Started
October 2022
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sanja Jelic, MD
Columbia University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.